Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Allurion Technologies ( (ALUR) ).
On February 23, 2026, Allurion Technologies announced that the U.S. Food and Drug Administration granted PMA approval for its Allurion Gastric Balloon System, featuring the swallowable Allurion Smart Capsule, for adults aged 22 to 65 with obesity and a BMI between 30 and 40 who have previously failed at least one weight-loss program. The capsule is swallowed in a brief office visit without surgery, endoscopy, or anesthesia, remains in the stomach for about four months to promote satiety and reduced intake, then empties and passes naturally, with the option for a second capsule within a 10‑month treatment window.
The approval gives Allurion access to an addressable U.S. market of roughly 80 million adults with obesity in the indicated BMI range, positioning the Smart Capsule as a non-invasive alternative or complement to GLP-1 drugs and bariatric surgery amid high discontinuation rates and weight regain with medications. Supported by real-world use in over 200,000 patients outside the U.S. and integrated with Allurion’s AI-enabled Virtual Care Suite, the system could strengthen the company’s competitive standing in the obesity-treatment market and expand options for providers and patients seeking reversible, repeatable weight-loss interventions.
The most recent analyst rating on (ALUR) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Allurion Technologies stock, see the ALUR Stock Forecast page.
Spark’s Take on ALUR Stock
According to Spark, TipRanks’ AI Analyst, ALUR is a Neutral.
Overall score is held back primarily by weak financial performance: contracting revenue, large ongoing losses, heavy cash burn, and negative equity. Offsetting factors include improving cost control and constructive FDA/regulatory and balance-sheet restructuring progress discussed on the earnings call, plus moderately positive technical momentum. Valuation remains difficult to support due to negative earnings and no dividend yield provided.
To see Spark’s full report on ALUR stock, click here.
More about Allurion Technologies
Allurion Technologies, Inc. is a medical technology company focused on metabolically healthy weight loss, built around its Allurion Program weight-loss platform. The program combines the FDA-approved Allurion Gastric Balloon System, featuring the swallowable, procedureless Allurion Smart Capsule, with its Allurion Virtual Care Suite of digital tools for patients and healthcare providers.
The Virtual Care Suite includes a mobile app for consumers, an insights platform for clinicians powered by the Iris AI Platform, and a connected scale to support remote monitoring. Allurion targets adults with obesity, particularly those seeking non-surgical, reversible alternatives to GLP-1 drugs and bariatric surgery within a structured lifestyle-modification framework.
Average Trading Volume: 98,700
Technical Sentiment Signal: Strong Sell
Current Market Cap: $14M
See more data about ALUR stock on TipRanks’ Stock Analysis page.